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Abstract
Introduction: A wide use of imaging techniques results in more frequent diagnosis of adrenal incidenataloma. 
Aim: To analyse the current state of knowledge on adrenal incidentaloma in adults in order to prepare practical management recom-
mendations. 
Methods: Following a discussion, the Polish Society of Endocrinology expert working group have analysed the available data and sum-
marised the analysis results in the form of recommendations. 
Imaging and hormonal assessment: Unenhanced adrenal computed tomography (CT) may be recommended as an initial assessment 
examination helpful in the differentiation between adenomas and “non-adenomatous” lesions. In the case of density > 10 Hounsfield 
units, CT with contrast medium washout assessment or MRI are recommended. However, in all patients with adrenal incidentaloma, 
hormonal assessment is recommended in order to exclude pheochromocytoma and hypercortisolism, notwithstanding the clinical pic-
ture or concomitant diseases. In addition, examination to exclude primary hyperaldosteronism is suggested in patients with diagnosed 
hypertension or hypokalaemia. 
Treatment: Surgical treatment should be recommended in patients with adrenal incidentaloma, where imaging examinations suggest 
a malignant lesion (oncological indication) or with confirmed hormonal activity (endocrinological indication). The basis of the surgical 
treatment is laparoscopic adrenalectomy. Patients with suspected pheochromocytoma must be pharmacologically prepared prior to sur-
gery. In patients not qualified for surgery, control examinations (imaging and laboratory tests) should be established individually, taking 
into consideration such features as the size, image, and growth dynamics of the tumour, clinical symptoms, hormonal tests results, and 
concomitant diseases. (Endokrynol Pol 2016; 67 (2): 234–258)
Key words: adrenal incidentaloma; adrenocortical carcinoma; pheochromocytoma; Cushing syndrome; hypercortisolism; management guidelines 
Streszczenie
Wstęp: Szerokie zastosowanie badań obrazowych klatki piersiowej i jamy brzusznej skutkuje coraz częstszym przypadkowym rozpo-
znawaniem zmian w nadnerczach.
Cel: Celem pracy była analiza dostępnej wiedzy dotyczącej postępowania w incydentaloma nadnerczy u dorosłych w celu przygotowania 
praktycznych zaleceń. 
Sposób przygotowania: Grupa robocza stworzona z ekspertów zgromadzonych w Polskim Towarzystwie Endokrynologicznym przeana-
lizowała jakość dostępnych danych i po dyskusji podsumowała wyniki analizy w postaci przygotowanych zaleceń. 
Ocena obrazowa i hormonalna: Jednofazowa tomografia komputerowa (CT) nadnerczy może być zalecana jako badanie w początkowej 
ocenie zmiany pozwalające odróżnić gruczolaki od innych zmian nie będących gruczolakami („nie-gruczolaki”). W przypadku gęstości 
zmiany > 10 jednostek Hounsfielda zaleca się wykonanie badania CT z oceną wypłukiwania środka cieniującego lub rezonansu magne-
prof. Tomasz Bednarczuk M.D., Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Banacha St. 1A, 
02–097 Warsaw, Poland, phone: +48 22 599 29 75, fax: +48 22 599 19 75, e-mail: tbednarczuk@wum.edu.pl 
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tycznego. U wszystkich chorych z incydentaloma nadnerczy, niezależnie od obrazu klinicznego oraz chorób współistniejących, zaleca się 
ocenę hormonalną w kierunku guza chromochłonnego oraz hiperkortyzolemii. Badania w kierunku pierwotnego hiperaldosteronizmu 
są wskazane u pacjentów z rozpoznanym nadciśnieniem tętniczym lub hipokaliemią. 
Leczenie: Leczenie operacyjne powinno być zastosowane u chorych z incydentaloma nadnercza o charakterystyce obrazowej mogącej 
odpowiadać nowotworom złośliwym (wskazania onkologiczne) lub potwierdzonej czynności hormonalnej (wskazania endokrynologicz-
ne). Podstawową metodą leczenia operacyjnego jest laparoskopowa adrenalektomia. Pacjenci z podejrzeniem guza chromochłonnego 
bezwzględnie wymagają przygotowania farmakologicznego do operacji. U chorych niezakwalifikowanych do operacji, badania kontrolne 
(obrazowe i laboratoryjne), należy ustalać indywidualnie, biorąc pod uwagę, między innymi wielkość, obraz i dynamikę wzrostu guza, 
objawy kliniczne, wyniki badań hormonalnych oraz choroby współistniejące. (Endokrynol Pol 2016; 67 (2): 234–258)
Słowa kluczowe: incydentaloma nadnercza; rak kory nadnerczy; pheochromocytoma; zespół Cushinga; hiperkortyzolemia; zalecenia postępowania 
I. The basic goals in the diagnosis and 
treatment of adrenal incidentaloma
An adrenal incidentaloma is a previously unsuspected 
adrenal mass with a diameter ≥ 1 cm discovered on 
chest or abdomen imaging examination [1–4]. Every 
suspicion of an adrenal lesion observed during ultra-
sound (US) must be confirmed by computed tomogra-
phy (CT) or magnetic resonance imaging (MRI). There 
are no reliable or absolute standards concerning adrenal 
thickness, although it is safe to assume that adrenal 
thickness in the transverse axis > 1 cm is abnormal. 
Nevertheless, the thickness of the normal adrenal, 
especially in the adrenal branches conjunction, may 
be larger; therefore, confirmation of lesions < 1 cm 
may be difficult. 
Wide use of imaging techniques results in more 
frequent diagnosis of adrenal lesions, which affects 
4% of middle-aged patients and increases to over 10% 
in the elderly. 
Adrenal lesions can be classified as benign or ma-
lignant, they may be hormonally active or inactive, as 
well as unilateral or bilateral (Table I). However, the 
majority of cases (about 80%) are constituted by benign 
adenomas or nodular adrenocortical hyperplasia. The 
incidence of adrenocortical carcinoma (ACC) is esti-
mated at about 5%, pheochromocytoma constitutes 
about 5%, and metastases about 2% (please refer to the 
subdivision concerning histopathological examination).
For diagnostic and therapeutic purposes, in patients 
with incidentaloma, two major goals should be set 
forward:
 — The diagnosis of all ACC cases. ACC is a rare ma-
lignant carcinoma, with a strong tendency for local 
invasion and distant metastases. The prognosis in 
ACC is poor (five-year survival <50%), with limited 
therapeutic options [5–6]. Thus, early diagnosis and 
radical surgical treatment are crucial.
 — The diagnosis of all hormonally active tumours. 
Failure to diagnose tumours secreting catechola-
mine, cortisol, and aldosterone may lead to life 
threatening or chronic complications. 
In order to achieve the aforementioned goals, it is 
necessary to analyse both the clinical picture and ad-
ditional examination results based on laboratory tests 
and imaging [7–9]. 
II. Which imaging examinations should 
be performed in adrenal incidentaloma 
patients?
The main goal of imaging examinations is the differ-
entiation between adenomas and “non-adenomas” 
which require further diagnostic steps for ACC, adrenal 
metastases, or pheochromocytoma. The basic imaging 
examinations include [10–12]:
1. Unenhanced adrenal CT
 — First-line imaging examination in adrenal tumour 
diagnostics may be unenhanced high-resolution CT 
(layers < 3 mm). Its advantage is low price, short 
duration, and no necessity to use a contrast medium. 
However, in some cases it is necessary to perform 
further imaging examinations.
 — On the basis of an unenhanced CT it is possible 
to asses such tumour features as the size (ad-
ditionally, in further tests it is possible to assess 
its growth dynamics), shape, radiation attenua-
tion coefficient (in Hounsfield units [HU]), and 
structure homogeneity (including calcifications, 
necrotic areas).
 — The basic examination interpretation: values smaller 
or equal to +10 HU represent a high lipid content 
and are typical for adenomas (sensitivity 71%, 
specificity 98%). In such cases, further imaging 
tests are usually not necessary. If the values exceed 
30 HU it may suggest a pheochromocytoma or 
a malignant tumour (ACC or adrenal metastases). In 
contrast, lesions with a radiation attenuation coef-
ficient between 11 and 30 HU are ambiguous; thus, 
in the differential diagnosis lipid-poor adenomas 
must be taken into account. Furthermore, lesions 
with a radiation attenuation coefficient < –20HU 
are characteristic for myelolipomas. 
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2. Adrenal CT — examination with contrast  
medium administration (washout assessment)
 — In numerous health centres it constitutes a first-line 
examination in adrenal tumour diagnosis. It is also 
performed when the unenhanced CT is ambiguous 
in terms of the tumour nature (adenoma or “non-
adenoma”), primary localisation (e.g. liver hilar 
tumour, pancreatic tumours), and infiltration of the 
surrounding tissues.
 — Adrenal CT with radiation attenuation evaluation 
is performed prior to contrast medium administra-
tion, in the first minute (enhancement assessment), 
as well as in the 10th or 15th minute after contrast 
administration (washout assessment).
 — In comparison to unenhanced CT, on the basis of 
this examination it is possible to assess the absolute 
and relative washout values (Table II) features of 
the surrounding tissues infiltration, as well as the 
presence of liver metastases. 
 — Basic interpretation: adenomas are characterised by 
faster washout – the attenuation coefficient returns 
quickly to basic values: 
• after 10 minutes, the absolute washout ≥ 50% 
(sensitivity 71–100%, specificity 80–98%), relative 
washout ≥ 40% (sensitivity 77–98%, specificity 
94–100%);
• after 15 minutes, the absolute washout ≥ 60% 
(sensitivity 86–88%, specificity 92–96%), relative 
washout ≥ 40% (sensitivity 96%, specificity 100%).
The method allows us to distinguish lipid-poor ad-
enomas from other adrenal tumours in some of cases. 
In the case of malignant tumours (ACC, metastases), 
the attenuation coefficient remains elevated. However, 
pheochromocytoma may present various washout charac-
teristics. Haematomas and cysts show a characteristic lack 
of density increase after contrast medium administration. 
3. Adrenal MRI (most frequently without  
contrast medium)
 — It is performed when unenhanced adrenal CT is 
ambiguous in terms of the tumour character. Ad-
ditionally, this examination is recommended if 
iodine-containing contrast medium administra-
tion is contraindicated (allergies to iodine con-
trast mediums, renal failure, hyperthyroidism). 
What is more, MRI without contrast medium is 
the method of choice in adrenal tumours during 
pregnancy. In fact, adrenal MRI is characterised 
by high sensitivity in the diagnosis of lipid-poor 
adenomas (90%).
 — Adrenal tumour MRI differentiation is based on 
chemical shift, where it is possible to obtain in-
Table I. Adrenal incidentaloma in adults
Malignant tumours Benign Lesions
1. Hormonally active tumours
— adrenocortical carcinoma#
— malignant pheochromocytoma
— adenoma secreting#:
cortisol#
aldosterone or
androgens
— pheochromocytoma#
— micro- and macronodular adrenal hyperplasia*
— congenital adrenal hyperplasia*
2. Hormonally inactive tumours
— adrenocortical carcinoma
— adrenal metastases*, #
— lymphoma
— non-secretory adenomas#
— other benign tumours (e.g. myelolipoma, angioma)
— inflammatory tumours (e.g. tuberculoma)*
— granulomas (e.g. sarcoidosis)*
— other (e.g. cysts, haematoma)
*Frequently bilateral; #the most common causes of tumours
Table II. Absolute and relative contrast medium washout in 
adrenal tumour CT
Parameter Formula
Absolute contrast medium washout  
(more frequent) 
D1’–(D10’ or D15’) ×100 
D1’–D0
Relative contrast medium washout D1’–(D10’ or D15’) ×100 
D1’
D0 — density (HU) prior to contrast medium administration; D1’ — density (HU) 
1 minute after contrast medium administration; D10’ — density (HU) 10 minutes 
after contrast medium administration; D15’ — density (HU) 15 minutes after 
contrast medium administration
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phase and out-of-phase images. They allow for the 
assessment of lipid content in the adrenal tumours 
with higher sensitivity than unenhanced CT. In 
out-of-phase images a decrease in signal intensity is 
observed (as compared to in-phase pictures) in the 
lipid containing lesions (adenoma, hyperplasia), thus 
making the lesions hypointense. However, signal 
intensity in tumours not containing lipids does not 
change (metastases, phaeochromocytomas, ACC).
 — Basic interpretation: adenoma and adrenocortical 
hyperplasia are characterised by a significant de-
crease of signal intensity in the out-of-phase. In fact, 
in the majority of cases, visual assessment (qualita-
tive) allows us to distinguish lipid-containing tu-
mours from other lesions. The signal Intensity index 
(SI index) calculated according to the formula: [(SI 
in phase–SI in out-of-phase)/SI in phase) × 100%] is 
employed when the visual assessment of the signal 
intensity decrease is ambiguous; values above 16% 
indicate adenoma. Pheochromocytoma present 
increased signal intensity in comparison to the liver 
and spleen in T2-weighted images; however, it is true 
only in 70% of cases. Similar images are observed 
also in some adrenal metastases. In fact, myelolipo-
mas are easy to diagnose in MRI (in fat-saturation 
sequences) due to the presence of the adipose tissue, 
but it frequently does not show a signal decrease in 
out-of-phase images. 
Complementary imaging tests include: 
 — abdominal cavity ultrasound — the main indication 
is the lesion size monitoring in cases where the le-
sion is visible in the US image [13];
— 123I-MIBG scintigraphy (or 131I-MIBG scintigraphy, 
metaiodobenzylguanidine scintigraphy) performed 
in the diagnosis of pheochromocytoma;
 — Positron Emission Tomography (PET) using 
F-fluorodeoxyglucose (FDG) — increased uptake 
suggests malignant tumours (ACC, metastases). False 
negative results may be however obtained in renal 
cell cancer metastases or low-grande lymphoma;
 — Iodine cholesterol scintigraphy — the major indi-
cation is ACTH-independent hypercortisolism in 
patients with bilateral adrenal tumours qualified 
for surgery (please refer also to “Examinations for 
primary hyperaldosteronism”).
4. Adrenal biopsy
Indications for adrenal biopsy are very limited. In fact, 
this examination may be considered in selected patients 
with suspected adrenal metastases of an unknown pri-
mary localisation, lymphoma, or adrenal tuberculosis 
if the diagnosis would change the course of treatment. 
A suspected pheochromocytoma or ACC constitute 
contraindication for biopsy. 
Basic interpretation of imaging examination results 
is shown in Table III. It is vital to bear in mind that in 
spite of the huge progress in imaging examinations, in 
a number of cases the diagnosis of “non-adenomatous” 
lesions is possible only after surgery, in the course of 
histopathological tests [14, 15]. 
III. Which hormonal tests should be 
performed in patients with adrenal 
incidentaloma?
Irrespective of the clinical picture or concomitant dis-
eases, all patients with adrenal incidentaloma should 
be assessed in terms of pheochromocytoma, as well as 
hypercortisolism [7, 9, 17–19]. Tests towards hyperaldo-
steronism are indicated in patients with hypertension 
or hypokalaemia [7, 9, 18]. Hormonal testing is usually 
not necessary in cases of a myelolipoma. 
1. Tests for hypercortisolism
Although incidentaloma is a lesion found incidentally, 
it is vital to draw attention to the clinical manifestations 
that may accompany increased glucocorticoid secretion. 
Cushing’s syndrome confirmation requires the pres-
entation of increased, autonomic cortisol secretion in 
two tests assessing the function of adrenocorticotropic 
axis. Basic screening tests in the diagnosis of hypercor-
tisolism comprise:
 — Overnight dexamethasone suppression test (fasting 
cortisol serum concentration assessment, between 
8–9 a.m. after oral 1 mg dexamethasone adminis-
tration at 11 p.m. the previous day). Basic inter-
pretation: cortisol concentration below 1.8 µg/dL 
(50 nmol/L) excludes hypercortisolism (sensitivity 
> 95%, specificity 80%). On the other hand, a corti-
sol concentration higher than 5 µg/dL (140 nmol/L) 
indicates Cushing’s syndrome (sensitivity 80%, 
specificity 95%). Thus, in incidentaloma diagnosis, 
an intermediate cutoff point is employed equal 
to 3.4 µg/dL (94 nmol/L), characterised by 97% 
sensitivity and 88% specificity in the diagnosis of 
Cushing’s syndrome (refer to subclinical hypercor-
tisolism). Moreover, in interpretation of dexametha-
sone suppression test, it is possible to obtain both 
false positive results, in the course of depression, 
alcoholism, anorexia nervosa, stress, renal failure, 
the administration of oestrogen, tamoxifen, carba-
mazepine, phenobarbital, phenytoin, pioglitazone, 
and rifampicin, as well as false negative results, in 
nephrotic syndrome, administration of itracona-
zole, diltiazem, and fluoxetine [18, 20]. 
 — Urinary free cortisol — increased excretion of free 
cortisol in 24-hour urine collection 1.5 times above 
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the upper limit established for a given laboratory 
indicates Cushing’s syndrome [17].
 — Late-night cortisol serum concentration (11 p.m. 
or 12 p.m.) above 5.4 µg/dL (140 nmol/L) indicates 
Cushing’s syndrome (sensitivity 97%, specificity 
88%). However, the disadvantage of this method is 
the necessity of patient hospitalisation. Late-night 
salivary cortisol tests are also available in Poland. 
However, depending on the method, reference 
values must be established in given laboratories.
If the screening test results are abnormal, further 
diagnosis in the referral centres is necessary in order 
to confirm the diagnosis and establish the aetiology of 
hypercortisolism (ACTH-dependent or ACTH-inde-
pendent Cushing’s syndrome).
The diagnosis of ACTH-independent, subclinical 
hypercortisolism remains controversial because the 
diagnostic criteria have not been clearly established 
[21]. If subclinical hypercortisolism is suspected, it is 
vital to consider the clinical picture (e.g. osteoporosis, 
visceral obesity, hypertension, diabetes) as well as the 
following results of additional tests (frequently 2–3 or 
3–4 criteria are provided):
 — 1 mg dexamethasone suppression test ≥ 3.4 µg/dL;
 — morning ACTH < 5 pg/mL;
 — urinary free cortisol above the upper limit;
 — cortisol 11:00 p.m.–12:00 p.m. ≥ 5.4 µg/dL;
 — other described criteria are as follows: decreased 
dehydroepiandrosterone sulphate (DHEA-S) con-
centration, lack of ACTH stimulation following CRH 
administration, the development of postoperative 
adrenocortical insufficiency, postoperative improve-
ment in clinical manifestations, autonomic gluco-
corticoid secretion in iodocholesterol scintigraphy.
2. Tests for pheochromocytoma
Patients with incidentally found pheochromocytoma in 
most cases (57%) either do not present with hyperten-
sion or it is mild or moderate in character. Moreover, 
patients usually do not show excessive stimulation of 
the adrenergic system. Thus the symptom triad: dia-
phoresis, headache, and palpitations was present in 
10% of patients diagnosed with pheochromocytoma [4].
Recommended screening tests in the diagnosis of 
pheochromocytoma are:
 — urinary fractionated metanephrines (sensitivity 
and specificity depends on the method employed, 
although the golden standard is high-performance 
liquid chromatography [HPLC] where sensitivity is 
95% and specificity 86%) or
 — plasma free metanephrines concentration (with 
the use of HPLC, sensitivity 96%, specificity 89%) 
[7, 22–24].
Unfortunately, in Poland the abovementioned tests 
are available in few referral centres. Although measur-
ing of urine unfractionated metanephrines constitutes 
one of the most frequently performed tests in Poland, 
it is no longer recommended in the diagnosis of pheo-
chromocytoma. Nevertheless, the low price and high 
sensitivity stemming from careful labelling makes this 
test useful especially in cases of symptomatic pheochro-
mocytoma or those larger than 2 cm [25]. 
Another valuable test may be assessing serum or 
plasma chromogranin A concentrations (sensitivity 
> 85%, specificity > 90%) [26–28], although there is 
the possibility of obtaining false positive results in 
the following cases: if the patient was treated with 
proton pump inhibitors or H2 receptor blockers, has 
concomitant neuroendocrine tumours (such as carci-
Table III. Characteristic features of adrenal tumours in imaging examinations
Adenoma Cancer Pheochromocytoma Metastasis
Size Usually < 4 cm Usually > 4 cm No rule No rule
Shape Round/circular Irregular Round/circular Irregular or Round/circular
Separation from the  
surrounding tissue
Sharp Blurred or sharp Sharp Blurred or sharp
Structure Homogenous Inhomogeneous (necrotic  
areas, calcifications)
Inhomogeneous  
in larger tumours
Homogenous (small tumours) 
or inhomogeneous (larger 
tumours)
Unenhanced CT 
density
≤ 10 HU > 10 HU (usually > 30) > 10 HU (usually > 30) > 10 HU (usually > 30)
Contrast washout* ≥ 50% in 10th minute < 50% in 10th minute Usually < 50%  
in 10th minute
< 50% in 10th minute
Lipid content in MRI Definite Lack or scant Lack Lack
Growth of the tumour Stable or slow  
(< 0.5 cm/year)
fast (> 2 cm/year) 
or very fast
Frequently slow  
(0.5–1 cm/year)
No rule, usually fast
*Absolute contrast medium washout; on the basis of [16]
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noid, gastrinoma, or glucagonoma), prostate cancer, 
with high levels of IgM rheumatoid factors, or some 
inflammatory diseases of the gastrointestinal tract (type 
A atrophic gastritis).
If pheochromocytoma is suspected on the basis 
of the clinical picture, imaging, or laboratory tests, 
the patient should be referred to a specialised centre. 
Moreover, in patients diagnosed with pheochromocy-
toma, it is vital to test for genetic mutations that have 
been demonstrated to be related with the development 
of pheochromocytoma. 
3. Tests for primary hyperaldosteronism 
The screening test for primary hyperaldosteronism is 
aldosterone-renin ratio (ARR) based on the ratio of al-
dosterone (ng/dL) and plasma renin activity (ng/mL/h) 
or renin concentration measured in the morning, two 
hours after upright standing, taken while sitting. Basic 
interpretation: in order to diagnose primary hyperal-
dosteronism ARR should be > 30, and aldosterone con-
centration should be above 10–15 ng/dL [29, 30]. When 
interpreting ARR it is necessary to take into consideration 
the influence of any taken medications (Table IV). Prior to 
the planned diagnostic procedures, potassium deficiency 
should be supplemented and if possible hypertension 
medications should be modified because long-lasting 
calcium channel blockers and a1-adrenolytics may 
minimally influence the ARR value. Additionally, a diet 
without sodium restrictions is recommended. 
Patients with abnormal results of the abovemen-
tioned markers require further diagnosis in referral 
centres. Should primary hyperaldosteronism be con-
firmed in patients qualified for surgical treatment, it is 
necessary to consider catheterisation of adrenal veins in 
order to assess the lateralisation of aldosterone secretion, 
independently of the adrenal tumour presence. Adrenal 
iodocholesterol scintigraphy is rarely employed. 
4. Tests for hyperandrogenism
In females with hyperandrogenic syndrome, total 
testosterone measurement is recommended along 
with dehydroepiandrosterone sulphate (DHEA-S) and 
17(OH)-progesterone levels. High concentrations of 
testosterone (over 200 ng/dL), DHEA-S (over 800 µg/ 
/dL), and 17(OH)-progesterone frequently accompany 
ACC [11, 31]. Abnormalities in androgen levels require 
differentiation with polycystic ovarian syndrome and 
congenital adrenal hyperplasia [32, 33].
IV. What are the indications for the surgical 
treatment of an incidentaloma?
Surgical treatment constitutes a crucial integral compo-
nent in managing patients with adrenal incidentaloma. 
Surgical treatment should be offered to patients with 
adrenal incidentaloma where imaging examinations 
suggest a malignant lesion (oncological recommenda-
tion) or with confirmed hormonal activity (endocrino-
logical recommendations). 
1. Oncological recommendations
The most important criterion is a radiological tumour 
image that does not correspond to an adrenal adenoma 
(density in unenhanced CT over 30 HU, contrast me-
dium washout <50% in the 10th minute or lack of lipids 
in MRI) (Table III).
Additional criteria include:
 — Tumour size (diameter > 5 cm);
 — Fast or very fast tumour growth (Table III).
Indications for the surgical removal of adrenal 
metastases should be approached individually if the 
primary tumour has been removed and no metastases 
have been confirmed.
2. Endocrinological indications:
 — All cases of a suspected pheochromocytoma because 
even asymptomatic tumours may be the cause of 
the hypertension crisis, e.g. during other surgical 
procedures.
 — ACTH — independent Cushing’s syndrome. Due 
to the increased mortality of Cushing’s syndrome 
patients, tumours overproducing cortisol should 
be removed. Surgical treatment recommendations 
may be difficult in bilateral adrenal tumours (indi-
cation for iodocholesterol scintigraphy). Surgical 
treatment of subclinical hypercortisolism patients is 
Table IV. Medications that can affect the ARR and the recommended time of their discontinuation prior to the test [7, 18, 29]
       Influence on
Medication group PRA Aldo ARR Discontinuation time prior to the tests
ACEI/ATRI ≠≠ Ø Ø 2 weeks
Progestogens ≠≠ ≠ Ø 4 weeks
Diuretics/spironolactone/eplerenone ≠≠ ≠ Ø 4 weeks
PRA — plasma renin activity; Aldo — aldosterone; ARR — aldosterone/plasma renin activity ratio; ACEI — angiotensin-converting-enzyme inhibitors;  
ATRI — angiotensin receptor inhibitors
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controversial. In fact, surgical intervention should be 
considered especially in younger patients suffering 
from diseases associated with cortisol excess (e.g. 
recent confirmation or deterioration of hyperten-
sion pharmacological control, type 2 diabetes, or 
osteoporosis) [21, 34, 35].
 — Primary hyperaldosteronism. In primary hyperaldo-
steronism patients in the course of adrenal adenoma 
(Conn’s syndrome) it is vital to consider surgical 
treatment first. 
 — Hyperandrogenic syndrome associated with adre-
nal tumour.
3. Types of surgery
The choice of the surgical method should be based 
primarily on the surgical team’s experience and skills. 
Additional factors influencing the decision comprise: 
tumour size, surgical treatment indications, concomi-
tant diseases, risk factors, anatomical conditions, the 
patients’ physique, and the team’s technical capabilities.
The invention of minimally invasive adrenal sur-
gery methods in the late 20th century changed modern 
surgery without changing indications for surgical 
procedures, their rules of conduct, or their goals and 
scope. In fact, the safety advantages and patient sat-
isfaction combined with a simultaneous decrease in 
perioperative and postoperative complications made 
the videoscopic/laparoscopic surgery the point of ref-
erence. The versatility of laparoscopic surgery (lateral 
access to the adrenals from the peritoneal cavity) has 
led to the fact that 85% of health centres employ it as a 
basic treatment method. Therefore, what should rather 
be discussed are not indications for this method, but 
cases where classical open surgery is advisable [36–38].
Adrenalectomy indications for classical open surgery:
 — Patients with larger adrenal tumours (> 8 cm);
 — ACC patients with invasive tumour features, such 
as local infiltration, lymph node enlargement, me-
tastases to distant organs;
 — Patients requiring adrenal reoperation.
Non-radical, adrenal sparing adrenalectomies are 
rarely performed. The aim of such operations is the 
removal of the lesion responsible for surgery indica-
tions (tumour) with the retention of a well-vascularised 
unchanged portion of the adrenal cortex. Thus, it 
allows adrenal function to be maintained and, as a 
consequence, to avoid substitutional treatment [37, 
39]. However, the indications for non-radical adrenal 
sparing adrenalectomy remain unclear. This kind of 
surgery may be considered in patients:
 — qualified for bilateral adrenalectomy;
 — with hereditary multiple endocrine neoplasia com-
prising pheochromocytoma;
 — with a pseudocyst or an endothelial adrenal cyst.
V. Preparations for surgery  
and postoperative care
1. Incidentally found pheochromocytoma 
The following aspects play a crucial role in patient 
preparation for surgery [24, 40–43]:
 — proper filling of vascular bed;
 — blood pressure normalisation, including controlling 
paroxysmal hypertension and symptoms depending 
on the circulating catecholamine excess which may 
be released during the surgery itself;
 — heart rate normalisation. 
The preparation period usually lasts 2–3 weeks 
when alpha receptor blockers are administered:
 — Doxazosin in a gradually increasing dose: from 1 mg 
to 12–16 mg daily, in the days prior to the surgery, 
usually divided into three doses,
 — Phenoxybezamine — 20–100 mg daily administered 
orally in 2–3 divided doses.
Calcium antagonists (dihydropyridine derivatives) 
may be used in connection with alpha blockers as a means 
of preparation for surgery. In patients with tachycardia 
or with concomitant arrhythmias, introducing selective 
beta-adrenolytics should be considered only after alpha 
receptor blockage. Hypovolaemia should be treated using 
increased salt and fluid oral intake, as well as intravenous 
0.9% sodium chloride infusions before surgery and dur-
ing its course. Sudden blood pressure rise during surgery 
should be controlled by administration of: IV phentola-
mine 2-5 mg (repeating the dosage if necessary), sodium 
nitroprusside, or urapidil. Nevertheless, hypotension is 
the greatest potential danger in post-op patients. Sudden 
catecholamine decrease leads to vascular bed dilation and 
reduced cardiac output. What is more, if combined with 
decreased blood volume and blood loss in the course of 
surgery, it may result in sudden blood pressure drops.
The following patient condition features are consid-
ered proper before the surgery:
 — if in the 24-hour period immediately before the 
surgery no significant high blood pressure episodes 
> 160/90 mm Hg appear, as well as no episodes of 
orthostatic hypotension < 80/45 mm Hg are noted;
 — if there is neither tachycardia at rest nor any signifi-
cant arrhythmia;
 — if there is no ST segment elevation and T-wave 
inversion in the ECG in the seven-day period prior 
to operation.
Due to the lack of clear histopathological diagnosis 
of pheochromocytoma, patients require lifelong am-
bulatory care.
2. Incidentally found primary hyperaldosteronism
Preparation for surgery requires potassium supplemen-
tation [9, 30, 44–46]. This process is achieved by a diet 
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that is low in sodium and rich in potassium, as well 
as by spironolactone administration 100–400 mg daily 
for a few weeks before the procedure. Blood pressure 
normalisation and normokalaemia are considered nec-
essary conditions in order to perform surgery. 
After surgery potassium supplements and spironol-
actone should be discontinued, and hypertension drugs 
should be gradually reduced. Moreover, hyperkalaemia 
may appear as a consequence of decreased aldosterone 
secretion by the adrenal gland. Usually, a sodium-rich 
diet is sufficient, although rarely patients also require 
the temporary administration of fludrocortisone. Hence, 
effective surgical treatment is based on the normalisation 
of aldosterone concentrations and plasma renin activity.
In the case of idiopathic bilateral adrenocortical 
hyperplasia, the method of choice is pharmacological 
treatment based on spirolactone administration, firstly 
100–200 mg daily. In order to continue the treatment, 
smaller doses of 50–100 mg daily are usually required. 
Another recommended medication is eplerenone 
(competitive aldosterone antagonist), which may be 
considered in the case of adrenocortical hyperplasia. 
3. Subclinical hypercortisolism
In the case of subclinical hypercortisolism steroidogen-
esis inhibitors are not employed. Patients with subclini-
cal overproduction of glucocorticoids always require 
steroid cover during and after the surgery. The patient 
should be administered 100–200 mg of hydrocortisone 
intravenously at the day of surgery, with gradually 
reduced dosage in the consecutive days until oral ad-
ministration. Postoperative adrenocortical insufficiency 
is the most conclusive confirmation of subclinical hy-
percortisolism. After successful surgical treatment the 
adrenal function normalises within 6–24 months. In fact, 
permanent adrenocortical insufficiency after unilateral 
surgical procedure is extremely rare [7, 9, 21, 36].
4. Adrenocortical cancer (ACC)
In patients with suspected ACC, the surgical procedure 
should be performed with steroid cover if hormonally 
active adrenal tumours were found in the preoperative 
period. After surgery, mitotane administration should 
be considered [5, 6, 31].
5. Adrenocortical insufficiency
Bilateral adrenal tumours, such as metastases, lym-
phoma, and tuberculosis, may cause adrenal insuffi-
ciency, if 90% of the adrenal cortex has been destroyed. 
In fact, the most common cause are metastatic lesions 
in the adrenals. In this group of patients — if they are 
qualified for surgical removal of the abnormal adrenal 
gland — the surgical procedure should be performed 
with steroid cover. 
6. Hormonally inactive adrenal tumours
The majority of diagnosed adrenal tumours do not 
show any clinical or subclinical hormonal activity, and 
thus they do not require any preparation for surgery. 
Postoperative treatment depends on histopathologi-
cal diagnosis and adrenal function assessment after 
surgery, which, apart from the interview and physical 
examination, includes cortisol and ACTH concentra-
tion assessment, as well as the electrolyte serum con-
centration estimation in the morning. The percentage 
of patients who develop postoperative adrenocortical 
insufficiency or a decrease in adrenal reserve after 
unilateral adrenalectomy is small [41]. 
VI. What are the problems with 
histopathological adrenal tumour 
assessment?
Despite great progress in histopathological techniques, 
such as immunohistochemistry, morphological diagno-
sis of resected abnormal adrenal masses still remains a 
challenge and may lead to mistakes, e.g. the percentage 
of initial incorrect histopathological diagnoses in Ger-
many was estimated at 13% [5]. However, neoplasms, 
both primary and metastatic, constitute the majority of 
resected adrenal lesions (Table V).
The challenges pathomorphologists face during 
diagnosis are directly related to the four basic issues 
they strive to establish:
1. Is it a neoplasm or is it a non-neoplastic lesion?
2. Is the tumour primary or secondary in nature (ad-
renal metastasis)?
3. Does the tumour originate in the cortex or the ad-
renal medulla?
4. Is the neoplasm benign (e.g. adrenal adenoma) or it 
is malignant (e.g. adrenocortical carcinoma)?
Ad 1. A large portion of adrenal lesions are non-
neoplastic tumours, for example: inflammatory le-
sions (mainly tuberculous), nodular adrenocortical 
hyperplasia, or adrenal cysts (both pseudocysts and 
epithelial-lined/true cysts). However, they are relatively 
rarely treated surgically and thus constitute a minority 
of postoperative morphological diagnoses. [48, 49].
Ad 2. Adrenals are relatively common sites of 
metastatic tumours. They are the fourth most fre-
quent location of metastases (after the lungs, liver, and 
bones). According to the literature, metastases to the 
adrenals are present in 27% of patients dying due to 
carcinomas. Most often, these metastases are from lung, 
breast, kidney, and gastrointestinal tract carcinomas, as 
well as from malignant melanomas. In certain cases, 
differentiation of metastases with primary tumours, 
usually cortical, may constitute a problem; this applies 
mainly to tumours with clear cytoplasm, such as clear 
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cell renal cell carcinoma (CCRCC), or tumours with 
a trabecular growth pattern, such as hepatocellular car-
cinoma (HCC). In such cases, the immunohistochemical 
markers of cortical differentiation play a major role. 
Among the numerous markers used in the course of 
primary adrenocortical tumour identification, the most 
practical (with relatively high sensitivity and specificity) 
are steroidogenic transcription factor-1 (Ad4BP/SF-1), 
melanoma-A marker (MART-1), and inhibin-alpha. 
However, one has to bear in mind that in some percent-
age of extra-adrenal tumours, the above-mentioned 
markers may give a false positive result, e.g. RCC pre-
sents a positive reaction with melan-A in 10% of cases 
and in 9% of cases with inhibin-alpha [50]. It is helpful 
to use immunohistochemical markers that are typically 
positive for the primary malignancy, e.g. Hep-Par-1 
positive reaction in HCC, PAX8 positive in RCC, or TTF-
1 positive in the large portion of lung carcinomas. The 
majority of metastatic tumours retain both the primary 
tumour morphology and immunophenotype, thus the 
immunohistochemical panel does not differ from the 
diagnostic standards for primary lesions. It is vital to 
stress the importance of clinical data, such as detailed 
information regarding past neoplastic diseases, in the 
planning of a morphological differential diagnosis con-
cerning the primary and secondary adrenal tumours. 
Ad 3. In routine histopathological haematoxylin and 
eosin staining (H&E), differentiation between pheo-
chromocytoma and adrenocortical tumour (especially 
ACC) may pose certain difficulties. Hence, it may be 
very helpful to use immunohistochemistry. Chro-
mogranin A is most often used in the differentiation 
of cortical and medullary tumours because it is almost 
always negative in cortical tumours and remains posi-
tive in 100% of pheochromocytoma cases. Other neu-
roendocrine markers, such as synaptophysin or NSE, 
are less frequently employed. In fact, although they 
nearly always exhibit a positive reaction in medullary 
tumours, they also remain positive in a large group of 
cortical tumours, e.g. synaptophysin exhibits a positive 
reaction in 67% of cortical tumours. Typical markers 
for adrenocortical tumours may show positivity in 
a small group of phaeochromocytomas, e.g. a-inhibin 
and melan-A in 6% of cases and calretinin in 14% of 
phaeochromocytomas [51]
Ad 4. The most crucial issue in adrenal tumour mor-
phological analysis is the assessment of the lesion’s ma-
lignancy potential, especially in adrenocortical tumours. 
Apart from local invasion and distant metastases, there 
are hardly any isolated, single morphological features 
of malignancy. Nevertheless, basic macroscopic features 
are useful in the initial differential diagnosis. Adreno-
cortical adenomas usually weigh below 50 g, they are 
well-circumscribed, non-encapsulated, or encapsulated 
lesions (with a true or pseudocapsule). Macroscopically, 
they usually have a homogenous, solid, and uniform 
structure, most frequently yellowish or yellowish-
orange colour. ACCs, on the other hand, are typically 
large lesions weighing over 100 g and measuring more 
than 6 cm. Grossly, they are heterogenous tumours, 
varied in colour (from yellowish-orange to brown), of 
lobulated structure with fibrous bands, frequently with 
areas of necrosis and haemorrhage. ACCs may be well-
demarcated, but they frequently infiltrate the surround-
ing tissues and adjacent organs, e.g. the kidney or liver. 
Nevertheless, numerous microscopic parameters 
play a major role in the assessment of adrenocortical 
tumour malignant potential. To date, few multi-para-
metric systems assessing the primary adrenocortical 
tumour histologically for malignant potential have 
been developed. Some of them are based only on 
morphological features, others also include clinical and 
biochemical criteria. The most commonly used and the 
most verified criteria for assessing malignant potential 
in adrenocortical tumours is the Weiss system, which is 
also recommended by the Polish Society of Pathologists 
[49]. It is based on the assessment of nine histological 
features, each equal to one point in the scoring system. 
It is not a perfect system, its greatest disadvantage being 
poor reproducibility and subjectivity in the assessment 
of certain parameters. Therefore, Aubert et al. suggested 
its modification with the exclusion of the most contro-
versial features (Table VI). Tumours scoring three or 
more points in each system correlate with malignancy 
and are diagnosed as ACCs [53].
Table V. WHO classification of adrenal tumours [47]
PRiMARy ADRenAL tuMouRs
Adrenal cortical tumours
Adrenal cortical carcinoma 8370/3
Adrenal cortical adenoma 8370/0
Adrenal medullary tumours
Malignant pheochromocytoma 8700/3
Benign pheochromocytoma 8700/0
Composite Pheochromocytoma/Paraganglioma
other adrenal tumours
Adenomatoid tumour 9054/0
Sex-cord stromal tumor 8590/1
Myelolipoma 8870/0
Teratoma 9080/1
Schwannoma 9560/0
Ganglioneuroma 9490/0
Angiosarcoma 9120/3
seConDARy tuMoRs
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Another frequently employed system of measuring 
the adrenocortical tumour malignancy potential is the 
van Slooten system, which analyses seven histological 
features attributing a numerical score (1.6–9.0). A total 
value of the features, also known as the van Slooten In-
dex (VSI), ≥ 8 correlates with malignant behaviour [54]. 
It is worth bearing in mind that, due to the mor-
phological and clinical distinctiveness of adrenocortical 
tumours in children (usually less aggressive clinical 
course with a similar histopathological picture), the 
abovementioned systems may be employed only in 
adult patients (over 20 years of age). What is more, 
using Weiss system criteria, as well as the modified 
Weiss system, may also be problematic in cases of one 
adrenocortical tumour subtype, i.e. oncocytic adreno-
cortical tumour [51, 53–56].
Similarly to adrenocortical tumours, the assessment 
of pheochromocytoma malignancy also constitutes 
a challenge for the histopathological diagnosis. On the 
basis of the updated WHO classification of tumours, 
malignant pheochromocytoma is defined exclusively 
on the basis of the presence of metastases at sites where 
paraganglial tissue is not normally found. A significant 
challenge in the morphological diagnosis of pheochro-
mocytoma is the assessment of the tumour’s malignant 
potential before metastases occur. Moreover, there are 
no clearly defined criteria concerning differentiation 
between benign and malignant pheochromocytoma. 
The most frequent microscopic features in malignant 
tumours are: nodular structure, confluent necrosis, 
absence of hyaline globules, high mitotic index, atypical 
mitotic figures, absence of sustentacular cells (identified 
by immunohistochemical staining with S100 protein), 
as well as Ki-67 (MIB-1) proliferative index above 2.5%. 
Similarly to adrenocortical tumours, in the diagnosis 
of pheochromocytoma, scoring systems are employed 
based on a number of morphological features [53]. 
Thompson’s system, also known as Pheochromocytoma 
of the Adrenal Gland Scoring Scale (PASS score), is most 
frequently used. It is based on the analysis of numerous 
morphological features where 1–2 points are attributed. 
Two-point features include: the tumour’s structure with 
large nests or diffuse growth, the presence of necrosis, 
high cellularity, cellular monotony, presence of spindle 
shaped tumour cells, more than three mitoses for 
10 high-power fields, atypical mitoses, and extension of 
the tumour into adjacent fatty tissue. One-point features 
include: invasion of tumour cells into vessels, infiltration 
of the capsule, nuclear pleomorphism, as well as nuclear 
hyperchromasia. Each tumour may receive as many 
as 20 points. Benign phaeochromocytomas have fewer 
than four points in the PASS system, malignant ones have 
more than six points, although patients scoring more 
than four points should followed-up due to the risk of 
tumour recurrence. A critical approach to this system is 
recommended. Apart from Thomason’s system, which is 
based on histological features, other suggestions regard-
ing pheochromocytoma differentiation are presented 
in the literature. The most vital one is Kimura’s scoring 
system, which is based not only on assessment of the 
histological features but also on the Ki-67 proliferative 
index and the type of catecholamines secreted by the 
tumour [54]. However, it is worth remembering that there 
is no golden histopathological standard that would be 
accepted by everyone when it comes to differentiating 
between benign and malignant phaeochromocytomas.
VII. How to monitor adrenal tumours  
not qualified for surgical treatment
There is no clear agreement regarding monitoring 
of adrenal incidentalomas that are not qualified for 
surgical treatment. Control tests (both imaging and 
laboratory) should be planned individually taking into 
consideration such factors as tumour size, image and 
growth dynamics, clinical manifestations, hormonal 
tests results, as well as concomitant diseases, including 
neoplasms [57–63].
Table VI. Histological criteria for assessment of malignant potential in adrenocortical tumours [53]
Weiss system Modified Weiss system 
High nuclear grade (grade 3 or 4 based on Fuhrman criteria) √ –
Mitotic rate greater than 5 per 50 high-power fields √  √ × 2
Atypical mitoses √ √
Clear cells comprising 25% or less of the of tumour √  √ × 2
Diffuse architecture in over 1/3 of tumour √ –
Necrosis √ √
Venous invasion (smooth muscle in wall) √ –
Sinusoidal invasion (no smooth muscle in wall) √ –
Capsular invasion √ √
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1. Imaging tests
 — Basic tests monitoring tumour size comprise: US of 
the abdominal cavity and unenhanced adrenal CT. US 
constitutes an inexpensive and reliable method moni-
toring adrenal tumours, especially those larger than 
3 cm in diameter localised in the right adrenal gland. 
 — When the tumour is ≤ 3 cm in diameter and resembles 
a typical lipid-rich adenoma, imaging tests are recom-
mended every 12 months. In the cases of larger tu-
mours, or those with a less characteristic phenotype, 
it is worth considering check-ups every 3–6 months 
within the first year, and later every 12 months.
 — If the adrenal lesion is not oncologically suspicious 
and is stable, monitoring may be ceased after four 
years. In further observation, the risk of malignant 
transformation is practically non-existent. 
2. Hormonal tests
 — In adrenal tumours which are not hormonally ac-
tive ”based on” on clinical examination, monitoring 
includes only a selective hormonal assessment every 
12 months. A screening with 1 mg dexamethasone 
suppression test is recommended; screening tests for 
pheochromocytoma may be considered. Tumours 
larger than 3 cm are more frequently hormonally 
active than smaller lesions [61]. The risk of an ex-
cessive hormonal secretion by an adrenal tumour 
reaches a plateau after 3–5 years [58]; hence, further 
control is not necessary.
 — Patients with suspected subclinical hypercortisolism 
require control tests assessing adrenocortical axis 
function as well as a precise control of the diseases 
associated with an excess of glucocorticoids (obesity, 
diabetes, hypertension, osteoporosis).
 — The risk of developing pheochromocytoma in an 
initially unsuspicious adrenal tumour is very low. 
Unfortunately, the CT picture in the aforementioned 
cases may suggest lipid-poor adrenocortical adeno-
mas. Thus, in such a case hormonal tests may be key 
for the diagnosis.
Figure 1. Management of adrenal incidentaloma. In numerous centres adrenal CT with contrast medium (washout assessment) is the 
first line examination in the diagnosis of adrenal tumours; @ — individual approach to focal lesions — the clinical picture should be 
considered, as well as concomitant diseases, tumour size, and growth dynamics. Indications for other tests, e.g. scintigraphy, PET-
CT, and adrenal biopsy, should be taken into account; *search for primary localisation. Surgical removal of adrenal metastasis may 
be considered in isolated metastasis and primary localisation removal; **indications for surgery in patients with hormonally inactive 
adenomas should be approached individually, taking into consideration lesion size, growth dynamics, the patient’s age, and concomitant 
diseases; #hormonally active adrenal tumours (especially phaeochromocytomas) require pharmacological treatment prior to surgery; 
CT — computed tomography; MRI — magnetic resonance imaging; HU — hounsfield units
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VIII. Conclusions
A simplified algorithm for the diagnostic management 
is shown in Figure 1.
 — Adrenal incidentaloma is an abnormal lesion ≥ 1 
cm in diameter, found incidentally during imaging 
examination. Every focal lesion in adrenals found 
in US requires confirmation by CT or MRI.
 — The main goal of imaging tests is the differentiation 
between adenomas and “non-adenomas” requiring 
further diagnosis for ACC, adrenal metastasis or 
pheochromocytoma. Basic imaging tests include: 
unenhanced adrenal CT, adrenal CT with contrast 
medium (washout assessment), and adrenal MRI 
(most frequently without contrast medium). 
 — In all adrenal incidentaloma patients, notwithstand-
ing the clinical picture and concomitant diseases, 
tests for pheochromocytoma and hypercortisolism 
are recommended. Tests for primary hyperaldo-
steronism are indicated in patients with diagnosed 
hypertension and hypokalaemia. 
 — Adrenal incidentalomas with malignancy features 
in the imaging test (oncological recommendations), 
as well as those with diagnosed hormonal activity 
(endocrinology recommendations), require surgical 
treatment. The principal surgical procedure is vide-
oscopic/laparoscopic adrenalectomy. Hormonally 
active adrenal tumours (especially suspected pheo-
chromocytoma) require pharmacological treatment 
prior to surgery. 
 — Control tests (imaging and laboratory) in patients 
not qualified for surgical treatment should be 
planned individually taking into considerations 
such features as: tumour size and growth dynamics, 
clinical manifestations, hormonal test results, and 
concomitant diseases. 
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